FDA
-
-
-
-
-
-
-
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
-
-
-
-
-
-
-
Seres Therapeutics publishes research on VOWST mechanism in medical journals
-
-
-
-
-
-
-
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplan
-
-
-
-
-
-
-
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
-
-
-
-
-
-
-
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
-
-
-
-
-
-
-
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
-
-
-
-
-
-
-
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

